Pulmonary aspergillosis after treatment with infliximab in Still's disease and a literature review of Still's disease and pulmonary aspergillosis
EUROPEAN JOURNAL OF RHEUMATOLOGY, cilt.5, sa.1, ss.75-78, 2018 (ESCI, TRDizin)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 5 Sayı: 1
- Basım Tarihi: 2018
- Doi Numarası: 10.5152/eurjrheum.2016.15081
- Dergi Adı: EUROPEAN JOURNAL OF RHEUMATOLOGY
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.75-78
- Hacettepe Üniversitesi Adresli: Evet
Özet
The use of anti-tumor necrosis factor alpha (anti-TNF-alpha) agents has increased during the past decade in rheumatology practice. Opportunistic infections have been reported with anti-TNF-alpha agents in clinical trials and post-marketing usage. Aspergillus infection is a rare opportunistic infection that is associated with immunosuppression, and there are reported cases of pulmonary aspergillosis in various rheumatic diseases treated with anti-TNF-alpha agents. Here, we present the first case of pulmonary aspergillosis associated with infliximab treatment in a patient with Still's disease.